-
Breaking a vicious cycle of inflammationNovartis researchers aim to quash inflammation to treat chronic disease.
-
DiscoveryHelping clinical trial patients during a lockdownYan Zhao talks about how her team in China responded to an emerging public health crisis.
Discovery -
Access to HealthcareCancer didn’t stop for COVID-19Myriam Mendila describes how Novartis continued supporting cancer patients and healthcare professionals during the pandemic.
Access to Healthcare -
Access to HealthcareStreamlining systems to respond to COVID-19Paul Aliu and his team quickly address requests for Novartis medicines during the pandemic.
Access to Healthcare -
DiscoveryMoving from speculation to science during a pandemicFlorencia Segal’s experiences prepared her to lead the rapid design of a large COVID-19 clinical trial.
Discovery -
DiscoveryIt takes an R&D village to fight a pandemicGervais Tougas shares his experience working on a Novartis task force dedicated to fighting the COVID-19 pandemic.
Discovery -
From Our LabsA visual tour of scientific strategies for combating coronavirusResearchers around the world are collaborating to provide solutions to immediate and future challenges.
From Our Labs -
People and CultureGoing the extra mile to keep clinical trials on track during the COVID-19 pandemicA Novartis team couriers an experimental treatment across Europe to a patient as transit grinds to a halt.
People and Culture -
DiscoveryCOVID-19: Answering your top questionsNovartis CEO Vas Narasimhan answers questions about COVID-19.
Discovery -
DiscoveryVisualizing molecular gluesMolecular glues are a new type of medicine inspired by nature’s matchmakers.
Discovery -
Patient PerspectivesCaring for someone with heart failureCaring for someone with heart failure can be both demanding and rewarding. Learn about the impact of being a carer and the support that carers need.
Patient Perspectives -
The data42 program shows Novartis’ intent to go big on data and digitalNovartis is betting on both human inquisitiveness and computer expertise to harness the wealth of its digital research and development platform, data42.